Bellevue Group Ag Aurinia Pharmaceuticals Inc. Transaction History

Bellevue Group Ag

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$4.11 - $8.14 $6.4 Million - $12.7 Million	-1,556,179 Reduced 54.67%	1,290,278 $5.57 Million
Q3 2022 Nov 14, 2022	BUY	$6.66 - $12.39 $1.17 Million - $2.17 Million	175,044 Added 6.55%	2,846,457 $21.4 Million
Q2 2022 Aug 11, 2022	BUY	$8.95 - $12.8 $2.38 Million - $3.4 Million	265,588 Added 11.04%	2,671,413 $26.8 Million
Q1 2022 May 13, 2022	BUY	$10.05 - $22.48 $24.2 Million - $54.1 Million	2,405,825 New	2,405,825 $29.8 Million

214

58.3M

1.14M

1.51M

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $1.13B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

Stay updated on Bellevue Group Ag with notifications on news.